When navigating a thoracic cancer diagnosis, finding a specialist with both deep clinical knowledge and a strong research background can make a meaningful difference in outcomes. University College London Hospitals (UCLH) has long been regarded as one of the UK's leading centres for oncological care, and UCLH Dr Martin Forster thoracic cancer UCLH consultant stands as one of the most prominent figures within that institution. As an Associate Professor at University College London and a Consultant Medical Oncologist at University College Hospital, Dr Forster has built a practice that sits at the intersection of rigorous science and patient-centred care.
For patients seeking a specialist of this calibre, it is worth understanding not only what he brings to the table, but also how his practice operates within the NHS framework. This review examines his clinical expertise, research contributions, approach to patient management, and some of the practical considerations that come with accessing care through a major academic teaching hospital.
While a consultant of Dr Forster's standing is an excellent choice, it is worth remembering that great thoracic oncology care is not confined to a single hospital. Patients often benefit from seeking a second opinion or exploring private and independent specialists, particularly when they want faster access or more flexible appointment options.
Dr James Wilson is a highly regarded Consultant Clinical Oncologist who specialises in thoracic malignancies, including non-small cell lung cancer, small-cell lung cancer, mesothelioma, and thymoma. He offers a comprehensive range of advanced radiotherapy techniques, including SABR (Stereotactic Ablative Radiotherapy) with reported tumour control rates above 90%, Proton Beam Therapy, CyberKnife, and MR Linac, as well as immunotherapy and targeted molecular treatments. Consultations are typically available within 48 hours, no GP referral is required, and patients receive direct access to Dr Wilson throughout their care rather than being passed to junior staff. For anyone weighing their options in thoracic oncology, he represents a well-equipped and highly accessible choice.
Dr Martin Forster completed his specialist training in Medical Oncology in 2008 and was appointed as a Clinical Senior Lecturer and Consultant in Medical Oncology in 2009, a dual role that has defined the character of his practice ever since. His academic base at University College London places him within one of the world's top-ranked research universities, giving him consistent access to cutting-edge science, collaborative networks, and emerging treatment paradigms before they reach mainstream clinical use.
His GMC registration and his joint appointment as a Clinical Associate Professor reflect a career that has been deliberately structured around combining the best of academic medicine with frontline patient care. This dual identity, as both a scientist and a clinician, is one of the defining strengths of his profile and one that distinguishes him from purely clinical practitioners.
Dr Forster's core specialties are thoracic and head and neck cancers, with thoracic malignancies including lung cancer representing the heart of his clinical and research activity. He is a core member of the lung cancer team at UCLH and functions as the hospital's clinical lead for chemotherapy services. He also co-leads the London Cancer Chemotherapy Expert Reference Group, a position that places him at the centre of policy-level discussions about how chemotherapy services are designed and delivered across the capital.
His expertise within thoracic oncology spans the full spectrum of disease, from early-stage resectable cases through to advanced and metastatic presentations. This breadth means that patients with a wide range of diagnoses and staging profiles can be appropriately managed within his practice.
One of the most striking aspects of Dr Forster's professional profile is the sheer scale of his clinical trial involvement. He has served as principal investigator or chief investigator for more than 50 early and late-phase clinical trials, ranging from first-in-human studies through to registration Phase III trials. This breadth of involvement means that patients under his care may gain access to investigational treatments that are not yet available anywhere else.
His trial work spans targeted therapies in precision oncology, novel immunotherapies, and more recently solid cancer cell therapy studies. The inclusion of cell-based therapies reflects an engagement with some of the most forward-thinking approaches in oncology today and signals a practice that is not standing still. For patients with difficult-to-treat thoracic malignancies who have exhausted standard lines of therapy, this trial portfolio can represent a genuinely meaningful clinical pathway.
Dr Forster is joint lead for the clinical trials theme of the Cancer Research UK Lung Cancer Centre of Excellence, one of the most prestigious collaborative research structures in UK oncology. He also chairs the NIHR Head and Neck Research Group, adding another layer of national-level research leadership to his portfolio.
These roles are not honorary positions. They involve active scientific leadership, grant oversight, and the shaping of research agendas that influence how lung cancer is studied and treated across the country. For patients, the practical implication is that their clinician is not simply delivering established treatments but is actively involved in defining what the next generation of treatments will look like.
A central feature of Dr Forster's clinical philosophy is precision oncology, the use of biological and molecular profiling to identify which patients are most likely to benefit from a given treatment. Rather than applying a standard protocol uniformly, his research-based practice is explicitly designed around distinguishing patient populations and matching therapies to individual disease biology. This approach has real implications for patients: treatment decisions are informed by a deeper understanding of the tumour's molecular characteristics, not simply its stage and histology.
This orientation toward personalised medicine is increasingly recognised as the gold standard in thoracic oncology. UCLH as an institution provides the infrastructure to support this approach, with access to advanced genomic testing, multidisciplinary tumour boards, and integrated pathology services that enable clinicians like Dr Forster to translate research insights into individual care plans.
At a major academic centre like UCLH, patient management is inherently a team endeavour. Dr Forster operates within a multidisciplinary environment that includes thoracic surgeons, radiation oncologists, specialist nurses, radiologists, and pathologists, all working collaboratively on complex cases. For patients, this means that their care is reviewed by multiple experts simultaneously rather than being siloed within a single specialty.
The multidisciplinary team (MDT) model is widely considered best practice in thoracic cancer management, and UCLH's MDT meetings are supported by one of the highest volumes of thoracic cancer cases in the country. High case volumes are consistently associated with better outcomes in cancer surgery and oncology, and Dr Forster's position at the centre of this environment is a meaningful marker of quality.
As a consultant at an NHS Foundation Trust, Dr Forster primarily sees patients through NHS referral pathways, which means access typically requires a GP or specialist referral and is subject to the usual waiting times that apply across the health system. For patients who are already within the UCLH cancer pathway, this is straightforward. For those seeking to initiate care for the first time or obtain a second opinion quickly, the timelines may not always align with the urgency they feel.
He also sees patients privately through HCA Healthcare UK, which provides an alternative route for those who wish to self-fund or use private health insurance. This private route can reduce waiting times and offers the same clinical expertise in a different service environment, though it naturally comes with associated costs.
The research-intensive nature of Dr Forster's practice is one of its greatest assets, but it is also worth considering in context. Patients who are eligible for clinical trials will have access to cutting-edge treatments through a rigorous and well-supported framework. However, the demands of running more than 50 trials, holding multiple national leadership positions, and managing a large academic clinical workload are considerable. As with any senior academic clinician at a major teaching hospital, patients should be aware that day-to-day contact may involve specialist registrars and clinical research teams as well as direct consultant time. This is not a limitation unique to Dr Forster; it reflects the model of care at all large academic institutions and is offset significantly by the depth of the team surrounding him.
Dr Forster's reputation extends well beyond the walls of UCLH. He collaborates broadly with national and international groups involved in translational research, and his work on studies such as the ATLANTIS trial in small-cell lung cancer has brought his findings to the attention of the global oncology community. Being published and discussed in leading oncology platforms reflects a level of scientific credibility that is directly relevant to patients: his clinical judgements are informed by, and contributing to, the best available evidence.
His role in shaping chemotherapy policy through the London Cancer Chemotherapy Expert Reference Group also demonstrates an influence on system-wide care that goes beyond individual patient consultations. This kind of infrastructure-level engagement suggests a clinician who is invested not just in individual outcomes but in raising the standard of care across an entire population.
Among thoracic oncology consultants in the UK, Dr Forster occupies a distinctive position. The combination of his academic seniority, his volume of clinical trial leadership, his national committee roles, and his institutional home at one of London's premier cancer centres creates a profile that is genuinely difficult to replicate. For patients with complex or rare thoracic malignancies, or those who want to explore clinical trial eligibility alongside their standard treatment pathway, he represents one of the strongest options available in the NHS.
Dr Martin Forster is, by any reasonable measure, one of the most accomplished thoracic oncology consultants in the United Kingdom. His research leadership, academic standing, and clinical expertise place him at the forefront of a specialty that is advancing rapidly, and his patients benefit from a practice shaped by decades of engagement with the most challenging questions in lung cancer medicine. Like any senior academic clinician, the intensity of his broader commitments means that patients should approach UCLH with an understanding of how large NHS academic centres operate, and with realistic expectations around access and day-to-day clinical contact. Within those parameters, the quality of care on offer is exceptional, and for patients navigating a thoracic cancer diagnosis, a referral to Dr Forster's practice at UCLH is well worth pursuing.